Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (346)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2026
2219
3.330
 Why?
Head and Neck Neoplasms
16
2023
561
2.830
 Why?
Salivary Gland Neoplasms
8
2023
39
2.800
 Why?
Protein Kinase Inhibitors
15
2026
981
2.200
 Why?
Carcinoma, Squamous Cell
14
2019
641
2.190
 Why?
Pyridines
14
2026
609
2.110
 Why?
Thyroid Neoplasms
9
2024
370
1.800
 Why?
Carcinoma, Non-Small-Cell Lung
9
2026
1192
1.690
 Why?
Molecular Targeted Therapy
7
2021
441
1.620
 Why?
Neoplasm Recurrence, Local
7
2023
1150
1.530
 Why?
Protein-Tyrosine Kinases
4
2021
431
1.420
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2024
1969
1.410
 Why?
Neoplasms
20
2024
2913
1.390
 Why?
Lung Neoplasms
11
2026
2668
1.370
 Why?
Anilides
6
2024
84
1.320
 Why?
Gonanes
7
2016
23
1.310
 Why?
Proto-Oncogene Proteins
6
2021
625
1.290
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
37
1.230
 Why?
Cetuximab
7
2018
111
1.220
 Why?
Biomarkers, Tumor
8
2020
1329
1.190
 Why?
Adenocarcinoma
7
2024
926
1.180
 Why?
Phosphatidylinositol 3-Kinases
8
2017
383
0.800
 Why?
Pyrazoles
6
2026
517
0.780
 Why?
Mutation
13
2024
4090
0.740
 Why?
Carcinoma
3
2019
227
0.700
 Why?
Phytotherapy
2
2012
74
0.680
 Why?
Drugs, Investigational
2
2011
31
0.670
 Why?
Neoplasm Staging
15
2019
1475
0.660
 Why?
Cisplatin
6
2024
345
0.650
 Why?
Neoplasms, Second Primary
1
2021
102
0.610
 Why?
Papillomaviridae
4
2019
116
0.600
 Why?
Disease-Free Survival
10
2017
770
0.600
 Why?
Antineoplastic Agents, Immunological
2
2018
198
0.590
 Why?
Taxoids
3
2015
114
0.590
 Why?
Quinolines
5
2024
190
0.590
 Why?
Hedgehog Proteins
3
2015
200
0.580
 Why?
Carcinoma, Renal Cell
3
2017
230
0.580
 Why?
Pyrimidines
6
2026
530
0.570
 Why?
Humans
90
2026
145783
0.570
 Why?
Marijuana Smoking
2
2012
249
0.540
 Why?
Proto-Oncogene Proteins c-ret
5
2026
41
0.540
 Why?
Tumor Suppressor Proteins
2
2018
322
0.540
 Why?
Drug Resistance, Neoplasm
8
2024
883
0.540
 Why?
Middle Aged
44
2026
36309
0.510
 Why?
Kidney Neoplasms
3
2017
415
0.510
 Why?
Carcinoma, Mucoepidermoid
1
2017
17
0.510
 Why?
Colorectal Neoplasms
2
2016
868
0.500
 Why?
Aged
40
2026
26217
0.490
 Why?
Carcinoma, Transitional Cell
4
2017
68
0.490
 Why?
Ubiquitin Thiolesterase
1
2017
68
0.490
 Why?
Carcinoma, Ductal
1
2016
10
0.490
 Why?
Adenoma, Pleomorphic
1
2016
9
0.480
 Why?
Gene Rearrangement
2
2018
156
0.480
 Why?
Sulfones
2
2014
127
0.480
 Why?
Cannabinoids
2
2024
184
0.460
 Why?
Glycine
2
2014
186
0.460
 Why?
Maximum Tolerated Dose
5
2017
211
0.440
 Why?
Melanoma
1
2021
762
0.410
 Why?
Drug Interactions
6
2017
405
0.410
 Why?
Enzyme Inhibitors
3
2014
821
0.410
 Why?
Pyrroles
1
2014
220
0.390
 Why?
Iodine Radioisotopes
5
2024
138
0.390
 Why?
Gene Fusion
3
2023
30
0.390
 Why?
Signal Transduction
8
2018
5224
0.390
 Why?
Phenylurea Compounds
4
2024
119
0.380
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
231
0.380
 Why?
Genetic Variation
1
2018
977
0.380
 Why?
Male
45
2026
73010
0.380
 Why?
Lymph Nodes
4
2017
509
0.360
 Why?
Indazoles
3
2019
85
0.360
 Why?
Aged, 80 and over
16
2026
8347
0.360
 Why?
Female
46
2026
79045
0.360
 Why?
Quinazolines
1
2013
266
0.350
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
108
0.340
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
128
0.340
 Why?
Treatment Outcome
15
2024
11794
0.340
 Why?
Antibodies, Monoclonal, Humanized
4
2024
992
0.330
 Why?
Neoplasm Metastasis
6
2021
688
0.320
 Why?
Adult
27
2026
40881
0.300
 Why?
Prognosis
9
2021
4330
0.280
 Why?
ErbB Receptors
4
2017
635
0.270
 Why?
Benzamides
3
2022
226
0.270
 Why?
Papillomavirus Infections
3
2022
344
0.260
 Why?
Pharmacogenomic Variants
2
2018
35
0.260
 Why?
Urologic Neoplasms
2
2017
31
0.250
 Why?
Nitriles
2
2022
211
0.250
 Why?
Carcinoma, Ductal, Breast
1
2007
90
0.250
 Why?
Platinum
2
2024
48
0.240
 Why?
Mitoxantrone
1
2006
15
0.240
 Why?
Xenograft Model Antitumor Assays
7
2024
936
0.240
 Why?
Enterobacter
1
2006
9
0.240
 Why?
Tooth Diseases
1
2006
13
0.240
 Why?
Esophageal and Gastric Varices
1
2006
36
0.230
 Why?
Gene Expression Profiling
5
2018
1777
0.230
 Why?
Enterobacteriaceae Infections
1
2006
42
0.230
 Why?
Salivary Glands
2
2023
36
0.230
 Why?
Oropharyngeal Neoplasms
2
2016
56
0.230
 Why?
Acute Kidney Injury
3
2018
874
0.220
 Why?
Animals
16
2024
38101
0.220
 Why?
Serotonin 5-HT3 Receptor Antagonists
1
2024
5
0.220
 Why?
Chemoradiotherapy
4
2020
239
0.220
 Why?
Proto-Oncogene Proteins B-raf
2
2024
224
0.220
 Why?
Clinical Trials as Topic
3
2018
1062
0.210
 Why?
Receptors, Estrogen
1
2007
404
0.210
 Why?
Cannabis
1
2011
510
0.210
 Why?
Antiemetics
1
2024
51
0.210
 Why?
Immunotherapy
2
2023
668
0.210
 Why?
Urinary Bladder Neoplasms
2
2017
258
0.200
 Why?
Registries
2
2016
2410
0.200
 Why?
Liver Cirrhosis
1
2006
288
0.200
 Why?
Carcinoma, Adenoid Cystic
1
2023
19
0.200
 Why?
Models, Biological
3
2024
1764
0.200
 Why?
Combined Modality Therapy
4
2018
1271
0.200
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1450
0.200
 Why?
Bacteremia
1
2006
222
0.200
 Why?
Administration, Oral
3
2014
867
0.190
 Why?
Phenylthiohydantoin
1
2022
44
0.180
 Why?
Medical Marijuana
1
2024
122
0.180
 Why?
Survival Rate
5
2021
2094
0.170
 Why?
Radiation Pneumonitis
1
2021
31
0.170
 Why?
Drug Evaluation, Preclinical
2
2013
196
0.170
 Why?
Chemotherapy, Adjuvant
3
2017
427
0.170
 Why?
Survival Analysis
4
2020
1378
0.170
 Why?
Referral and Consultation
1
2007
869
0.170
 Why?
Carcinoma, Neuroendocrine
1
2021
37
0.160
 Why?
Disease Susceptibility
2
2020
344
0.160
 Why?
Adrenal Cortex Neoplasms
1
2021
70
0.160
 Why?
Adrenocortical Carcinoma
1
2021
72
0.160
 Why?
TOR Serine-Threonine Kinases
2
2016
456
0.160
 Why?
Gene Expression
2
2015
1478
0.160
 Why?
Cystectomy
2
2017
42
0.160
 Why?
SEER Program
1
2021
230
0.150
 Why?
Receptors, Nerve Growth Factor
1
2019
18
0.150
 Why?
Kaplan-Meier Estimate
3
2017
971
0.150
 Why?
DNA Mutational Analysis
2
2018
410
0.150
 Why?
Leukemia, Myeloid, Acute
1
2006
688
0.150
 Why?
Lymph Node Excision
2
2017
173
0.150
 Why?
Tracheal Neoplasms
1
2019
12
0.150
 Why?
Prostatic Neoplasms
1
2006
981
0.140
 Why?
Smad4 Protein
1
2019
34
0.140
 Why?
United States
8
2021
16126
0.140
 Why?
Positron Emission Tomography Computed Tomography
1
2020
118
0.140
 Why?
Alphapapillomavirus
2
2016
35
0.140
 Why?
Radiosurgery
1
2022
399
0.140
 Why?
Benzazepines
1
2018
35
0.140
 Why?
Genetic Heterogeneity
1
2019
66
0.140
 Why?
Risk
1
2021
923
0.140
 Why?
Genomics
3
2021
830
0.140
 Why?
Disease Management
2
2020
653
0.140
 Why?
Chromosome Aberrations
1
2019
166
0.140
 Why?
DNA Mismatch Repair
1
2018
53
0.130
 Why?
Tissue Fixation
1
2017
37
0.130
 Why?
Paraffin Embedding
1
2017
33
0.130
 Why?
Oncogenes
1
2018
118
0.130
 Why?
Smokers
1
2018
138
0.130
 Why?
Erlotinib Hydrochloride
1
2017
72
0.130
 Why?
Formaldehyde
1
2017
65
0.130
 Why?
Nasopharyngeal Neoplasms
1
2017
21
0.130
 Why?
Gene Deletion
1
2019
392
0.130
 Why?
Radiotherapy, Intensity-Modulated
1
2018
142
0.130
 Why?
DNA, Neoplasm
1
2017
160
0.130
 Why?
Neoplasm Grading
1
2018
311
0.130
 Why?
Health Services Needs and Demand
1
2019
280
0.130
 Why?
Gene Frequency
1
2018
489
0.120
 Why?
Chemoradiotherapy, Adjuvant
1
2016
44
0.120
 Why?
Salivary Ducts
1
2016
2
0.120
 Why?
Induction Chemotherapy
1
2017
88
0.120
 Why?
Laryngeal Neoplasms
1
2016
36
0.120
 Why?
Palliative Care
2
2018
1022
0.120
 Why?
Muscle, Smooth
1
2017
153
0.120
 Why?
Carboplatin
1
2016
164
0.120
 Why?
Nomograms
1
2016
59
0.120
 Why?
Dose-Response Relationship, Drug
3
2017
2028
0.120
 Why?
Hospice and Palliative Care Nursing
1
2018
115
0.120
 Why?
Database Management Systems
1
2016
51
0.120
 Why?
Prospective Studies
7
2024
8078
0.120
 Why?
Patient Navigation
1
2018
126
0.110
 Why?
Disease Progression
4
2018
2865
0.110
 Why?
Population Surveillance
1
2019
484
0.110
 Why?
Computational Biology
2
2018
669
0.110
 Why?
Young Adult
5
2021
14254
0.110
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Radiotherapy
1
2016
206
0.110
 Why?
Incidence
2
2019
2934
0.110
 Why?
Bone Neoplasms
1
2017
265
0.110
 Why?
Zinc Finger Protein GLI1
1
2014
25
0.110
 Why?
Genetic Testing
1
2018
483
0.110
 Why?
Retrospective Studies
8
2021
17330
0.110
 Why?
Retreatment
1
2014
80
0.110
 Why?
Hospice Care
1
2018
228
0.110
 Why?
Breast Neoplasms
1
2007
2393
0.110
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
21
0.100
 Why?
Piperazines
2
2018
375
0.100
 Why?
Neoplasms, Unknown Primary
1
2014
20
0.100
 Why?
Proto-Oncogene Proteins c-akt
1
2016
440
0.100
 Why?
Neoplastic Stem Cells
1
2018
409
0.100
 Why?
Paclitaxel
1
2015
259
0.100
 Why?
High-Throughput Nucleotide Sequencing
1
2017
534
0.100
 Why?
Patient Satisfaction
1
2018
712
0.100
 Why?
Veratrum Alkaloids
1
2013
20
0.100
 Why?
Promoter Regions, Genetic
1
2018
1247
0.100
 Why?
ras Proteins
1
2014
150
0.100
 Why?
Sulfonamides
1
2017
583
0.100
 Why?
Proportional Hazards Models
4
2017
1330
0.100
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
254
0.100
 Why?
PTEN Phosphohydrolase
1
2014
165
0.090
 Why?
Cell Cycle Proteins
2
2014
630
0.090
 Why?
Pilot Projects
2
2015
1898
0.090
 Why?
Imatinib Mesylate
1
2012
77
0.090
 Why?
Recombinant Fusion Proteins
1
2015
666
0.090
 Why?
Dasatinib
1
2012
58
0.090
 Why?
Risk Assessment
2
2019
3752
0.090
 Why?
Smoking
1
2019
1477
0.090
 Why?
Thiazoles
1
2012
142
0.090
 Why?
Aniline Compounds
1
2012
120
0.090
 Why?
Biomarkers
3
2018
4302
0.090
 Why?
Proto-Oncogene Proteins c-met
1
2012
76
0.090
 Why?
Hematopoietic Stem Cells
1
2015
435
0.090
 Why?
Biological Availability
1
2011
145
0.080
 Why?
Evidence-Based Medicine
2
2012
740
0.080
 Why?
Imidazoles
1
2012
247
0.080
 Why?
Phosphatidylinositol 3-Kinase
1
2011
25
0.080
 Why?
Mice
7
2024
18355
0.080
 Why?
Vascular Endothelial Growth Factor A
2
2024
552
0.080
 Why?
Adolescent
5
2022
22577
0.080
 Why?
Propensity Score
3
2017
377
0.080
 Why?
Tumor Microenvironment
1
2015
735
0.080
 Why?
Cell Line, Tumor
4
2024
3551
0.080
 Why?
Phenotype
1
2018
3170
0.080
 Why?
Algorithms
1
2018
1851
0.080
 Why?
Genetic Predisposition to Disease
1
2018
2399
0.080
 Why?
Kidney
1
2017
1497
0.070
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
109
0.070
 Why?
Multivariate Analysis
3
2017
1547
0.070
 Why?
Adaptation, Psychological
1
2014
719
0.070
 Why?
Brain Neoplasms
1
2018
1331
0.070
 Why?
Axilla
1
2007
51
0.060
 Why?
Clinical Trials, Phase I as Topic
2
2019
50
0.060
 Why?
Cohort Studies
4
2022
6033
0.060
 Why?
Neoadjuvant Therapy
2
2022
467
0.060
 Why?
Sentinel Lymph Node Biopsy
1
2007
117
0.060
 Why?
RNA, Messenger
1
2014
2805
0.060
 Why?
Transcription Factors
1
2014
1736
0.060
 Why?
Ligation
1
2006
91
0.060
 Why?
Mastectomy
1
2007
185
0.060
 Why?
Pain
1
2011
791
0.060
 Why?
Receptors, Progesterone
1
2007
244
0.060
 Why?
Stress, Psychological
1
2014
1151
0.060
 Why?
Creatinine
2
2018
515
0.060
 Why?
Fatal Outcome
1
2006
305
0.060
 Why?
Lymphatic Metastasis
2
2017
336
0.060
 Why?
Neoplasm Invasiveness
2
2017
508
0.060
 Why?
Caregivers
1
2014
1074
0.060
 Why?
Granisetron
1
2024
6
0.050
 Why?
Quinuclidines
1
2024
11
0.050
 Why?
Ondansetron
1
2024
20
0.050
 Why?
Double-Blind Method
2
2021
2064
0.050
 Why?
Isoquinolines
1
2024
43
0.050
 Why?
Skin Neoplasms
1
2012
853
0.050
 Why?
Gastrointestinal Hemorrhage
1
2006
138
0.050
 Why?
Risk Factors
1
2019
10919
0.050
 Why?
Neoplasm Proteins
1
2007
442
0.050
 Why?
Oncogene Proteins, Fusion
1
2026
212
0.050
 Why?
Glomerular Filtration Rate
2
2018
765
0.050
 Why?
Demography
2
2015
282
0.050
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.050
 Why?
Benzimidazoles
1
2024
189
0.050
 Why?
Recurrence
2
2018
1139
0.050
 Why?
Databases, Factual
2
2019
1491
0.040
 Why?
Four-Dimensional Computed Tomography
1
2021
38
0.040
 Why?
Androgen Antagonists
1
2022
91
0.040
 Why?
Immunohistochemistry
2
2018
1723
0.040
 Why?
Pulmonary Ventilation
1
2021
82
0.040
 Why?
Receptors, Androgen
1
2022
149
0.040
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
149
0.040
 Why?
Quality of Life
1
2013
3211
0.040
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Receptor, trkA
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
75
0.040
 Why?
Receptor, trkB
1
2019
39
0.040
 Why?
Trastuzumab
1
2019
118
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
174
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
40
0.030
 Why?
Phthalazines
1
2018
63
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2019
328
0.030
 Why?
Organic Cation Transporter 2
1
2017
8
0.030
 Why?
Glutathione S-Transferase pi
1
2017
10
0.030
 Why?
Retroperitoneal Space
1
2017
18
0.030
 Why?
Organic Cation Transport Proteins
1
2017
25
0.030
 Why?
Urinary Diversion
1
2017
13
0.030
 Why?
Tumor Cells, Cultured
1
2019
887
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
54
0.030
 Why?
Social Work
1
2018
85
0.030
 Why?
Membrane Glycoproteins
1
2019
499
0.030
 Why?
Margins of Excision
1
2017
50
0.030
 Why?
Immunophenotyping
1
2018
322
0.030
 Why?
Hospitals, Veterans
1
2018
258
0.030
 Why?
Laryngectomy
1
2016
17
0.030
 Why?
Kidney Function Tests
1
2017
156
0.030
 Why?
Oncologists
1
2017
47
0.030
 Why?
Cation Transport Proteins
1
2017
118
0.030
 Why?
Viral Core Proteins
1
2016
21
0.030
 Why?
Carcinogenesis
1
2018
228
0.030
 Why?
Pelvis
1
2017
125
0.030
 Why?
Regression Analysis
1
2018
1001
0.030
 Why?
Heart
1
2020
626
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
222
0.030
 Why?
Disease Models, Animal
2
2018
4568
0.030
 Why?
Internationality
1
2016
156
0.030
 Why?
Random Allocation
1
2016
365
0.030
 Why?
Antibodies, Monoclonal
1
2022
1505
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Anti-Bacterial Agents
1
2006
1925
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
15
0.030
 Why?
Myocardium
1
2020
935
0.030
 Why?
Robotic Surgical Procedures
1
2017
185
0.030
 Why?
Analysis of Variance
1
2017
1300
0.030
 Why?
Bone Marrow
1
2015
307
0.020
 Why?
Receptor, Notch2
1
2013
15
0.020
 Why?
Receptor Cross-Talk
1
2013
21
0.020
 Why?
Receptor, Notch1
1
2013
63
0.020
 Why?
Psychiatric Status Rating Scales
1
2014
533
0.020
 Why?
Metabolic Clearance Rate
1
2012
115
0.020
 Why?
Pandemics
1
2021
1711
0.020
 Why?
Gene Silencing
1
2013
202
0.020
 Why?
Nausea
1
2012
112
0.020
 Why?
Transcriptome
1
2018
1042
0.020
 Why?
Logistic Models
1
2017
2139
0.020
 Why?
Needs Assessment
1
2014
403
0.020
 Why?
Vomiting
1
2012
131
0.020
 Why?
Area Under Curve
1
2012
332
0.020
 Why?
Mice, Nude
1
2013
680
0.020
 Why?
Diarrhea
1
2012
193
0.020
 Why?
Blotting, Western
1
2013
1184
0.020
 Why?
Drug Administration Schedule
1
2012
782
0.020
 Why?
Cell Proliferation
1
2017
2514
0.020
 Why?
Fatigue
1
2012
366
0.020
 Why?
Time Factors
1
2019
7134
0.020
 Why?
Age Factors
1
2016
3346
0.020
 Why?
Lung
1
2021
4116
0.020
 Why?
Colorado
1
2018
4556
0.020
 Why?
Cytokines
1
2015
2069
0.020
 Why?
Follow-Up Studies
1
2016
5428
0.020
 Why?
Surveys and Questionnaires
1
2018
6085
0.010
 Why?
Cross-Sectional Studies
1
2014
5925
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (346) concept(s)
_
Co-Authors Expand Description
See all (69) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)